Onternabez

N/A

Report date: 2025/06/10 17:55:09
NME

Base Information

Drug NameOnternabez
Drug Alias Name[(1S,2S,5S)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanolCB2 receptor agonist (Tetra Bio-Pharma/Cellvera)PPP-003HU-308ARDS-003
ClassificationSmall molecules
Mechanisms of ActionCannabinoid CB2 receptor agonists
TargetsCannabinoid CB2 receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Ocular inflammationPain +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited Arab Emirates
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesHebrew UniversityUniversity Of Aberdeen
China Registration ClassN/A

Develop Information

Active CompaniesPanag PharmaCellvera Global Holdings LLCTetra Bio-Pharma Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Ocular inflammationPain +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A